A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.

@article{Herzog2013ARP,
  title={A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.},
  author={Thomas J. Herzog and Giovanni Scambia and Byoung Gie Kim and Catherine Lhomm{\'e} and Janina Markowska and Isabelle Laure Ray-Coquard and Jalid Sehouli and Nicoletta Colombo and Minghua Shan and Oana Petrenciuc and Amit Oza},
  journal={Gynecologic oncology},
  year={2013},
  volume={130 1},
  pages={25-30}
}
OBJECTIVES Sorafenib, an oral multikinase inhibitor of the VEGFR/PDGFR/Raf/MEK/ERK pathway, has shown potential activity in patients with recurrent ovarian cancer (OC). One strategy to prolong disease control and survival in patients with OC is maintenance therapy after achieving a complete response. A double-blind, randomized, placebo-controlled, phase II study to assess the efficacy and safety of maintenance therapy with sorafenib in the treatment of OC is presented. METHODS Patients with… CONTINUE READING